DAL MASO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.924
AS - Asia 2.401
EU - Europa 1.201
SA - Sud America 333
AF - Africa 327
Continente sconosciuto - Info sul continente non disponibili 63
OC - Oceania 42
Totale 7.291
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.687
SG - Singapore 643
VN - Vietnam 546
IT - Italia 462
CN - Cina 389
HK - Hong Kong 208
BR - Brasile 199
BD - Bangladesh 157
FR - Francia 89
DE - Germania 88
IN - India 65
NL - Olanda 64
GB - Regno Unito 63
SE - Svezia 61
FI - Finlandia 57
CA - Canada 52
PL - Polonia 52
IQ - Iraq 39
TR - Turchia 31
AR - Argentina 30
MX - Messico 28
RU - Federazione Russa 27
JP - Giappone 22
PK - Pakistan 22
SA - Arabia Saudita 22
CO - Colombia 21
ID - Indonesia 19
ZA - Sudafrica 19
EC - Ecuador 18
KR - Corea 18
CR - Costa Rica 17
PH - Filippine 17
BJ - Benin 16
ES - Italia 16
IL - Israele 16
JM - Giamaica 15
AU - Australia 14
MA - Marocco 14
AE - Emirati Arabi Uniti 13
AT - Austria 13
DO - Repubblica Dominicana 13
PT - Portogallo 13
TN - Tunisia 13
VE - Venezuela 13
AZ - Azerbaigian 12
CL - Cile 12
GR - Grecia 12
JO - Giordania 12
AL - Albania 11
AO - Angola 11
CH - Svizzera 11
DZ - Algeria 11
IE - Irlanda 11
LC - Santa Lucia 11
NI - Nicaragua 11
RE - Reunion 11
TJ - Tagikistan 11
TT - Trinidad e Tobago 11
UA - Ucraina 11
UZ - Uzbekistan 11
XK - ???statistics.table.value.countryCode.XK??? 11
AF - Afghanistan, Repubblica islamica di 10
CZ - Repubblica Ceca 10
KH - Cambogia 10
MN - Mongolia 10
PE - Perù 10
ZM - Zambia 10
BF - Burkina Faso 9
BO - Bolivia 9
CI - Costa d'Avorio 9
CU - Cuba 9
EG - Egitto 9
KE - Kenya 9
NP - Nepal 9
SD - Sudan 9
BA - Bosnia-Erzegovina 8
BZ - Belize 8
CV - Capo Verde 8
EE - Estonia 8
HR - Croazia 8
LB - Libano 8
LT - Lituania 8
ME - Montenegro 8
MG - Madagascar 8
MR - Mauritania 8
MZ - Mozambico 8
NC - Nuova Caledonia 8
PS - Palestinian Territory 8
PY - Paraguay 8
RS - Serbia 8
SI - Slovenia 8
TH - Thailandia 8
ZW - Zimbabwe 8
BE - Belgio 7
CG - Congo 7
CM - Camerun 7
CW - ???statistics.table.value.countryCode.CW??? 7
DJ - Gibuti 7
GA - Gabon 7
GE - Georgia 7
Totale 6.917
Salva come PNG Salva come JPEG
Città #
Ashburn 438
Singapore 382
San Jose 299
Fairfield 179
Hong Kong 179
Ho Chi Minh City 157
Hanoi 144
Chandler 134
Santa Clara 119
Beijing 80
Los Angeles 71
Council Bluffs 69
Seattle 57
Cambridge 56
New York 56
Woodbridge 56
Houston 55
Milan 52
Da Nang 50
Padova 49
Boardman 39
Chicago 39
Ann Arbor 36
Wilmington 35
Helsinki 30
Lauterbourg 30
San Diego 28
Bytom 26
São Paulo 25
Buffalo 24
Rome 23
Hefei 22
Dallas 21
Munich 21
Haiphong 20
London 20
Padua 20
Orem 18
Medford 17
North Charleston 17
Princeton 17
Cotonou 16
Frankfurt am Main 16
Nuremberg 15
Turku 15
Baghdad 14
Des Moines 14
Istanbul 14
Montreal 14
Naples 13
Baku 12
Guangzhou 12
Johannesburg 12
San José 12
Seoul 12
Turin 12
Amman 11
Amsterdam 11
Castries 11
Dushanbe 11
Roxbury 11
The Dalles 11
Tokyo 11
Warsaw 11
Athens 10
Bologna 10
Brooklyn 10
Lahore 10
Lusaka 10
Tashkent 10
Venice 10
Abidjan 9
Biên Hòa 9
Chennai 9
Denver 9
Figino 9
Hải Dương 9
Kingston 9
Managua 9
Mexico City 9
Mosier 9
Nairobi 9
Paris 9
Phnom Penh 9
Pune 9
Redondo Beach 9
Salt Lake City 9
Stockholm 9
Ulan Bator 9
Antananarivo 8
Columbus 8
Dublin 8
Elk Grove Village 8
Lappeenranta 8
Luanda 8
Nouakchott 8
Noumea 8
Phoenix 8
Quito 8
Tallinn 8
Totale 3.821
Salva come PNG Salva come JPEG
Nome #
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial 345
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 336
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 300
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 300
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 280
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 278
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 278
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 276
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 257
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 254
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 254
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 248
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 237
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 227
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 224
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 222
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 209
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 204
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 203
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 198
The role of liver kinase B1 in small cell lung cancer: association with prognosis and tumor immune microenvironment features 191
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 190
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer 189
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 184
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 183
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 180
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 180
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 180
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis 179
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 157
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 141
Machine Learning Identifies a Distinct Microbiota Signature in Immune Checkpoint Inhibitor Colitis Compared with Inflammatory Bowel Disease 89
Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort 80
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study 38
Totale 7.291
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.043
article - articoli 19.681
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022322 0 0 54 9 26 52 60 9 13 18 25 56
2022/2023270 31 39 15 38 31 21 5 20 53 6 11 0
2023/2024264 21 21 27 28 17 40 18 24 21 13 22 12
2024/2025966 4 69 46 34 135 17 20 89 78 46 165 263
2025/20264.470 238 285 508 649 344 192 820 292 442 254 247 199
2026/2027621 367 174 80 0 0 0 0 0 0 0 0 0
Totale 7.291